Arthrobacter luteus

Arthrobacter luteus: A Comprehensive Reference

1. Identity, Taxonomy, and Natural Sources

Arthrobacter luteus (abbreviated ALU) is a species of gram-positive bacteria in the genus Arthrobacter. It is facultatively anaerobic, pleomorphic, branching, non-motile, non-sporulating, non-acid-fast, catalase-positive, and rod-shaped, with dimensions of 0.6–1.0 μm × 0.8–10.0 μm.

The genus Arthrobacter was created by Conn and Dimmick in 1947, and belongs to the Actinobacteria class, the Actinobacteridae subclass, the Actinomycetales order, the Micrococcineae suborder, and the Micrococcaceae family. Arthrobacter belongs to the ecologically and industrially important class Actinobacteria, family Micrococcaceae, which includes microorganisms that live in soil, subterranean cave silts, sea, glacier silts, sewage, water sludge, aerial surfaces of plants, vegetables, fish, and various animal species.

Arthrobacter luteus was isolated from brewery sewage in research conducted in Takasaki, Japan in 1969. The isolation team studied the bacteria taxonomically and found them to be gram-positive, facultatively anaerobic, pleomorphic, branching, non-motile, non-sporulating, non-acid-fast, and catalase-positive rods. The bacteria also reduced nitrate, hydrolyzed starch, and liquefied gelatin, along with producing acids from carbohydrates. They compared the isolated bacteria with 18 other strands of similar microorganisms and found them to be in the genus Arthrobacter, but corresponding to no previously described species. Thus, the name "Arthrobacter luteus" was given to the isolates.

The species is formally registered under the ATCC strain designation ATCC 21606. The nomenclature of the restriction enzyme derived from this organism follows standard convention: the first letter "A" of AluI designates the genus "Arthrobacter," while the lower case letters "lu" designate the species "luteus." The soil-dwelling bacteria of the genus Arthrobacter belong to the Actinobacteria phylum, first defined as a group in 1928 and then officially proposed as a genus in 1947; Arthrobacter spp. are readily found in sewage and many types of soils, including desert, agricultural, rhizosphere, and Antarctic soils.

Common Names and Synonyms

• Arthrobacter luteus (formal species name)
• ALU (standard abbreviation in molecular biology)
• Cellulosimicrobium cellulans (a reclassified synonym noted in some genetic databases; the glucanase gene of A. luteus is sometimes listed under this designation)

Addgene and related genetic databases list the glucan hydrolase (glucan endo-1,3-beta-glucosidase) gene of this organism under the species entry Cellulosimicrobium cellulans (Arthrobacter luteus), reflecting a historical reclassification in some taxonomy databases.

2. Key Enzymes (Active Compounds) Produced by Arthrobacter luteus

The scientific and biotechnological significance of Arthrobacter luteus derives almost entirely from two categories of enzyme it produces: the AluI restriction endonuclease and the yeast-cell-wall-lysing enzyme complex known commercially as Zymolyase (also called lyticase). A third category—alkaline proteases—is a component of the zymolyase complex.

2.1 AluI Restriction Endonuclease

A restriction endonuclease produced by Arthrobacter luteus has been isolated, and the nucleotide sequence at the cleavage site has been characterized. The cleavage occurs at the center of a palindromic tetranucleotide sequence, giving even-ended (blunt-ended) duplex DNA fragments phosphorylated at the 5′-end. A palindromic tetranucleotide is a sequence with 4 nucleotides that can be read the same backward as forward.

AluI recognizes the palindromic sequence 5′ AGCT 3′, cleaving between the G and C residues, producing blunt-ended DNA molecules. The restriction endonuclease cleaves SV40 form I DNA into 32 fragments, which is quite unusual since most other restriction enzymes cleave much fewer.

A new restriction-like endonuclease, AluI, was partially purified from Arthrobacter luteus; this enzyme cleaves bacteriophage λ DNA, adenovirus-2 DNA, and simian virus 40 DNA at many sites, including all sites cleaved by the endonuclease HindIII from Haemophilus influenzae serotype d.

The Alu retrotransposon—a short interspersed nuclear element found in the human genome—is named after the bacterium's abbreviation. Alu elements comprise a short length of DNA originally characterized by the action of the Arthrobacter luteus (Alu) restriction endonuclease; over 25% of CpGs in the human genome reside within Alu elements.

2.2 Zymolyase / Lyticase (β-Glucanase Complex)

Zymolyase (also known as lyticase, sometimes misspelled as Zymolase) is an enzyme mixture used to degrade the cell wall of yeast and form spheroplasts. Essential activities of zymolyase include β-1,3-glucan laminaripentao-hydrolase activity and β-1,3-glucanase activity. A common source of zymolyase is the Actinobacteria Arthrobacter luteus.

Zymolyase, produced by a submerged culture of Arthrobacter luteus, has strong lytic activity against living yeast cell walls to produce protoplast or spheroplast of various strains of yeast cells. The essential enzyme for the lytic activity of Zymolyase is β-1,3-glucan laminaripentaohydrolase, which hydrolyzes linear glucose polymers with β-1,3-linkages and releases specifically laminaripentaose as the main and minimum product unit.

Zymolyase is reported to be a complex enzyme comprising Zymolyase A (β-1,3-glucan laminaripentaohydrolase) and Zymolyase B (alkaline protease), where the alkaline protease may change the structure of the yeast cell wall to facilitate penetration of Zymolyase A; Zymolyase A alone is unable to lyse yeast cell walls.

The full enzyme complement of the lyticase/zymolyase preparation includes:

• β-(1→3)-glucan laminaripentaohydrolase, together with additional β-(1→3)-glucanase, protease, and mannanase activities.
• The ability to break down both β (1→3) and β (1→4) bonds between glucose units.

This enzyme product is produced by deep fermentation of Arthrobacter luteus and purified by ammonium sulfate precipitation. There are two main commercial preparations: Zymolyase-20T and Zymolyase-100T, having lytic activity of 20,000 units/g and 100,000 units/g respectively; Zymolyase-20T is an ammonium sulfate precipitate, while Zymolyase-100T is a further purified preparation produced by affinity chromatography.

2.3 Biochemical Characteristics of the Organism

The bacterium reduces nitrate, hydrolyzes starch, and liquefies gelatin, along with producing acids from carbohydrates. Some Arthrobacter species are psychrophilic and psychrotrophic, can use a wide range of organic substrates as sole or principal sources of carbon and energy, and do not require vitamins or other organic growth factors.

3. Traditional and Historical Use

Arthrobacter luteus itself was not explicitly referenced in ancient herbal remedies; its broader family of soil-dwelling microbes has played a subtle role in some traditional contexts. These bacteria are naturally present in many herbal preparations, contributing to the fermentation and breakdown of plant materials, thereby enhancing nutrient availability and the bioactivity of herbal compounds.

The formal scientific history of Arthrobacter luteus begins with its isolation in 1969 from brewery sewage in Japan. The original taxonomic description of Arthrobacter luteus nov. sp. isolated from brewery sewage was published in the Journal of General and Applied Microbiology in 1969 (Kaneko, Kitamura, and Yamamoto). A follow-up paper in 1972 by the same group, also in the Journal of General and Applied Microbiology (volume 18, pages 57–71), described the lysis of viable yeast cells by enzymes of Arthrobacter luteus.

Arthrobacter luteus was first recognized for its role in biotechnology, where its enzymes—such as restriction endonucleases—were used in genetic research and molecular biology. Its ability to produce enzymes that break down complex carbohydrates and proteins has led to explorations of its utility in food processing and dietary supplementation.

There is no documented pre-modern or ethnobotanical tradition of deliberate use of Arthrobacter luteus as a medicinal or nutritional agent. Its emergence as a named ingredient in the dietary supplement industry is a contemporary phenomenon, appearing in multi-ingredient enzyme and probiotic formulations in the late twentieth and early twenty-first centuries.

4. Preparations and Dosage Forms

In commercial contexts, Arthrobacter luteus appears in two distinct product categories:

4.1 Research-Grade Enzyme Preparations

The yeast lytic enzyme from Arthrobacter luteus is assigned CAS Number 37340-57-1 and is supplied as a lyophilized powder. Commercial lyophilized preparations are available in grades of ≥200 units/mg solid, ≥2,000 units/mg protein, and free-of-DNA-contaminant grades suitable for microbiome research and diagnostic kit manufacturing.

Optimal conditions for lysis of viable yeast cells are pH 7.5 at 35°C; for hydrolysis of yeast glucan, optimal conditions are pH 6.5 at 45°C. Optimal Zymolyase activity is at 30°–37°C; lytic activity ceases at higher temperatures.

When stored as a powdered product at 30°C, the enzyme loses approximately 70% of its activity within 3 months.

4.2 Dietary Supplement Preparations

In dietary supplement contexts, Arthrobacter luteus appears most commonly as a listed source organism in enzyme-based digestive supplement blends and multi-enzyme formulations. No peer-reviewed clinical literature specifying dosage of Arthrobacter luteus-derived enzymes in human dietary supplement trials has been identified. The organisms or their enzyme products are sometimes incorporated into formulations alongside other microbial enzymes, probiotics, or plant-based ingredients.

5. Established Mechanisms of Action

5.1 Yeast Cell Wall Lysis (β-1,3-Glucanase Activity)

Lyticase (the zymolyase preparation from A. luteus) hydrolyzes poly-β(1→3)-glucose such as yeast cell wall glucan. It is a lysing enzyme that extracts DNA from yeast cells by inducing partial spheroplast formation; spheroplasts are subsequently lysed to release their contents. Lyticase is preferred to digest cell walls of yeast, which are difficult to disrupt because the cell walls may form capsules or resistant spores.

The lytic spectrum of lyticase has been reported to be useful for lysis of species from the genera Ashbya, Candida, Debaryomyces, Eremothecium, Endomyces, Hansenula, Hanseniaspora, Kloeckera, Kluyveromyces, Lipomyces, Metschikowia, Pichia, Pullularia, Torulopsis, Saccharomyces, Saccharomycopsis, Saccharomycodes, and Schwanniomyces.

5.2 AluI Restriction Endonuclease Activity

A restriction endonuclease enzyme extracted from A. luteus acts at the center of a palindromic tetranucleotide sequence to give even-ended duplex DNA fragments phosphorylated at the 5′-end. The restriction site AluI itself is a 4-base cutter: AG/CT.

The AluI restriction-modification (RM) system includes a DNA-methyltransferase that methylates the recognition sequence 5′-AGCT-3′ at position C5; such modification prevents DNA from hydrolysis by restriction endonuclease AluI.

5.3 Proposed Mechanisms Relevant to Supplement Claims

Supplement label language and industry literature have proposed several mechanisms by which Arthrobacter luteus-derived enzymes might exert digestive benefits in humans. These proposed mechanisms rest on the enzyme biochemistry described above, extrapolated to a human gastrointestinal context:

• Complex carbohydrate hydrolysis: In the food and medicinal industries, β-1,3-D-glucanase has been employed for removing the cell wall of fungi such as yeast under mild conditions, because the cell wall makes it difficult to extract various physicochemically unstable nutrients, vitamins, and enzymes from the cell.
• Proposed gut-flora modulation: No peer-reviewed human clinical studies have directly linked the ingestion of Arthrobacter luteus-derived enzymes to specific, measured changes in human gut microbiota composition.

6. Scientific Evidence by Area of Use

6.1 Digestive Health and Enzyme Activity

Scientific validation of Arthrobacter luteus as a nutritional ingredient is still in its early stages. Preclinical studies have shown that certain enzymes derived from this bacterium may enhance the digestibility of nutrients and support gut health by aiding in the breakdown of dietary components.

Some research has indicated that metabolites produced by Arthrobacter luteus could possess antioxidant properties, which may contribute to overall well-being. However, comprehensive clinical studies in humans are limited, and definitive health benefits have yet to be firmly established.

Evidence strength: Preliminary. No peer-reviewed, controlled human clinical trials specifically evaluating orally administered Arthrobacter luteus or its purified enzyme products for digestive health outcomes in humans were identified in searches of PubMed/PMC or institutional health databases. The existing enzyme biochemistry is well-characterized for in vitro and laboratory applications, but this does not constitute clinical evidence of benefit in human consumers.

6.2 Biotechnology and Molecular Biology Applications (Established, Non-Clinical)

The most robustly evidenced applications of Arthrobacter luteus-derived products are in laboratory molecular biology and microbiology, not in human health:

• Lyticase from Arthrobacter luteus has been used for resuspending cells to extract high-molecular-weight DNA for polymerase chain reaction (PCR) fingerprint analyses. The lyticase enzyme is frequently used in fungal research, particularly for species identification using PCR-based techniques.
• Digestion of yeast and fungal cell walls is necessary for many experimental procedures including spheroplasting, immunofluorescence, transformation, protein purification, and others. The use of lytic enzymes like Zymolyase is routinely used for digestion in these applications.
• The zymolyase preparation from Arthrobacter luteus, with its beta-1,3 glucanase activity, has been shown to remove the electron-dense outer layer of the Pneumocystis carinii cell wall, exposing an electron-lucent layer—a finding relevant to infectious disease research but not to dietary supplementation.

6.3 Fungal Cell Wall Biology and Potential Candida-Related Research

Because zymolyase from Arthrobacter luteus is active against Candida species cell walls in laboratory settings, some supplement formulations have been marketed with reference to yeast/candida balance. However, zymolyase from Arthrobacter luteus is labeled explicitly "for research use only" by major biochemical suppliers, and not for sale to patients. No peer-reviewed clinical trial evidence was identified supporting a therapeutic or preventive role for orally ingested Arthrobacter luteus preparations in candidiasis or yeast overgrowth conditions in humans.

6.4 AluI Enzyme and Genomics (Non-Clinical)

Renatured DNA from humans and many other eukaryotes is known to contain 300-nucleotide duplex regions formed from renatured repeated sequences, widely believed to be interspersed with single-copy DNA sequences. At least half of these 300-nucleotide duplexes share a cleavage site for the restriction enzyme AluI, located 170 nucleotides from one end. This Alu family of repeated sequences makes up at least 3% of the human genome and is present in several hundred thousand copies. This AluI endonuclease activity is relevant exclusively to laboratory molecular biology and has no established direct relevance to dietary supplementation outcomes.

7. Body Systems and Health Areas Associated With Arthrobacter luteus

In the supplement industry, Arthrobacter luteus is associated primarily with the following health areas, though the evidence basis for each is characterized below:

• Gastrointestinal / Digestive System: Its inclusion in nutritional products is associated with supporting digestive health, as its enzymes can aid in the breakdown of complex carbohydrates and proteins, improving nutrient absorption and gut flora balance. This claim is based on the known in vitro enzyme activity of the β-glucanase and protease components of the zymolyase preparation, extrapolated to human digestive contexts. Human clinical evidence is absent.
• Immune System (proposed): The enzymatic disruption of yeast cell walls is postulated to affect exposure of β-glucan polysaccharides, which are separately documented to have immunomodulatory effects. However, this represents a theoretical extrapolation; no human trials of Arthrobacter luteus preparations for immune endpoints have been identified.
• Molecular Biology Research Tools: The restriction endonuclease AluI has been instrumental in human genome mapping, particularly in characterizing Alu repeat elements. This is a scientific application, not a health application.

8. Dosage Forms Reported in Sources

No standardized human dietary supplement dosages for Arthrobacter luteus are established in peer-reviewed literature or government health authority guidance. The following dosage forms are documented in laboratory and commercial biochemical supply contexts:

• Two preparations of Zymolyase are commercially available: Zymolyase-20T with lytic activity of 20,000 units/g and Zymolyase-100T with lytic activity of 100,000 units/g.
• Lyophilized powders are available at activity specifications of ≥200 units/mg solid and ≥2,000 units/mg protein.
• One unit of lytic activity is defined as that amount which indicates a 30% decrease in absorbance at 800 nm of the reaction mixture after incubation for 2 hours at 25°C with gentle shaking.
• For the AluI restriction endonuclease, one unit is defined as the amount required to hydrolyze 1 μg of Lambda DNA in 1 hour at 37°C in a total reaction volume of 50 μl.

No human clinical trial has been identified that specifies an oral dose of Arthrobacter luteus or its enzyme products for dietary supplementation. Dosages used in human supplement products on the market are determined by manufacturers and are not derived from published clinical dose-finding studies.

9. Safety Considerations

9.1 Pathogenicity Profile of the Genus Arthrobacter

Arthrobacter strains are widely distributed in the environment, mainly in soil, and can sometimes represent the majority of bacterial groups in aerobic plate counts of soil specimens. Arthrobacter strains have relatively low pathogenic potential but can be pathogenic to immunocompromised hosts.

Strains of Arthrobacter spp. have been very rarely described as causing disease in humans; case reports have described occasional subacute infective endocarditis, bacteremia, postoperative endophthalmitis, a Whipple's disease-like syndrome, and phlebitis. Clinical microbiologists have increasingly recognized the diversity of coryneform bacteria in clinical specimens.

Arthrobacter has rarely been isolated from human clinical specimens; identified species associated with clinical cases include Arthrobacter cumminsii, Arthrobacter oxydans, Arthrobacter luteolus, and Arthrobacter albus, with reports of septicemia in immunocompromised patients and isolation from human urine specimens. It should be noted that Arthrobacter luteolus is a distinct species from Arthrobacter luteus.

Several Arthrobacter species—including A. cumminsii, A. woluwensis, A. creatinolyticus, A. luteolus nov. sp., and A. albus nov. sp.—are considered opportunistic pathogens because they have been isolated from human clinical specimens such as skin, urine, and blood cultures. Their role in diseases is not proven and their pathological significance has not yet been fully assessed.

Arthrobacter strains have relatively low pathogenic potential but can be pathogenic to immunocompromised hosts. In published case reports of Arthrobacter woluwensis bacteremia, four of six patients demonstrated features of poor immunity, including AIDS, terminal colon cancer, extreme old age, and multiple myeloma under chemotherapy treatment.

9.2 Enzyme Preparation Safety

Commercial sources of zymolyase may have some residual protease activity, which is relevant to both stability and potential allergenicity considerations for any enzymatic preparation intended for oral use.

All major biochemical suppliers of zymolyase and lyticase from Arthrobacter luteus explicitly label their products as for research use only and not for use in patients or for medical applications. MedChemExpress cautions that the product "has not been fully validated for medical applications" and is "for research use only."

9.3 Regulatory Status

No entry for Arthrobacter luteus as a dietary ingredient appears in the NIH Office of Dietary Supplements databases, the EFSA Novel Foods catalogue, or WHO/FAO monographs on food-related microorganisms. The organism does not appear on the U.S. FDA's Generally Recognized As Safe (GRAS) list as of available records. It has not been evaluated by the European Medicines Agency (EMA), ESCOP, the German Commission E, or the Cochrane Collaboration for any therapeutic indication.

Arthrobacter species have been of great interest in biotechnology and bioremediation applications, with numerous studies exploring Arthrobacter metabolic pathways and their ability to degrade a wide variety of pollutants such as pesticides and heavy metals, which contexts are distinct from dietary supplementation.

9.4 Notable Gaps in Safety Data

No published peer-reviewed toxicological studies, acute or chronic oral toxicity studies in animals or humans, allergenicity assessments, or pharmacokinetic studies of orally administered Arthrobacter luteus-derived enzyme preparations as dietary supplements were identified. The absence of such data represents a significant gap in the safety evidence base for any human supplemental use.

10. Overall Evidence Assessment

Arthrobacter luteus is a well-characterized soil bacterium whose scientific importance is firmly established in molecular biology (as the source of the AluI restriction endonuclease, one of the most widely used tools in recombinant DNA technology) and in laboratory yeast research (as the source of the zymolyase/lyticase enzyme complex). Both of these applications are extensively documented in peer-reviewed literature and patent records.

Its emergence as a named ingredient in dietary supplements is a separate and much more thinly evidenced phenomenon. Scientific validation of Arthrobacter luteus as a nutritional ingredient is still in its early stages; preclinical studies have shown that certain enzymes derived from this bacterium may enhance the digestibility of nutrients and support gut health by aiding in the breakdown of dietary components. Some research has indicated that metabolites produced by Arthrobacter luteus could possess antioxidant properties, but comprehensive clinical studies in humans are limited, and definitive health benefits have yet to be firmly established.

No human randomized controlled trials, systematic reviews, or government health authority evaluations of Arthrobacter luteus as a dietary supplement ingredient were identified. The evidence base for any health claim associated with oral administration of this organism or its enzyme products to humans is currently absent at the clinical level. Claims appearing in supplement marketing are unsupported by published clinical evidence and should be evaluated critically.

References

• Wikipedia: Arthrobacter luteus
• Sigma-Aldrich: Lyticase from Arthrobacter luteus — Product Data
• Sigma-Aldrich: Lyticase from Arthrobacter luteus — Substance Page
• Nacalai: Zymolyase (from Arthrobacter luteus) — Product Information Sheet (PDF)
• Nacalai USA: Zymolyase from Arthrobacter luteus
• Wikipedia: Zymolyase
• ScienceDirect: A specific endonuclease from Arthrobacter luteus (Journal of Molecular Biology, 1976)
• ScienceDirect: Arthrobacter luteus restriction endonuclease cleavage map of ΦX174 RF DNA (Virology, 1975)
• ACS Publications (Biochemistry): Nucleotide sequence analysis of DNA. 28. Arthrobacter luteus restriction endonuclease recognition sequence
• Google Patents: US5334526A — Cloning and expression of AluI restriction endonuclease
• ScienceDirect Topics: Arthrobacter (Agricultural and Biological Sciences overview)
• ScienceDirect Topics: Arthrobacter (Medicine and Dentistry overview)
• ScienceDirect Topics: Arthrobacter (Pharmacology and Toxicology overview)
• ScienceDirect: Bacteria belonging to the genus Arthrobacter as novel source of natural pigments (Food Research International, 2014)
• Microbiology Society: Review of the taxonomy of the genus Arthrobacter (IJSEM, 2016)
• PMC / Pathogens: Arthrobacter woluwensis Bacteremia: A Clinical and Genomic Report (2021)
• LPSN (DSMZ): Genus Arthrobacter — Taxonomic Record
• Zymo Research: Zymolyase Yeast Lytic Enzyme (from Arthrobacter luteus)
• Creative Enzymes: Native Arthrobacter luteus Lyticase
• MedChemExpress: Zymolyase, Arthrobacter luteus — Data Sheet (PDF)
• SibEnzyme Scientific Library: New Restriction Endonuclease AluBI from Arthrobacter luteus B
• iGEM Parts Registry: BBa_K2711000 — Glucan hydrolase from Arthrobacter luteus
• Springer: The Genus Arthrobacter (Chapter in The Prokaryotes)
• PMC: Taxonomy, Physiology, and Natural Products of Actinobacteria (Microbiology and Molecular Biology Reviews, 2016)
• Caring Sunshine: Ingredient — Arthrobacter luteus
• AMS Bio: Comparison of Zymolyase vs Lyticase & Glusulase (PDF)
• Public Health Agency of Canada: Pathogen Safety Data Sheet — Micrococcus spp. (Micrococcaceae family)